Maravai Lifesciences Holdings Inc (MRVI)
Healthcare
Biotechnology
6.60 $
-2.7%
vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Maravai Lifesciences Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
2.4$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
148Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
68.6%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.7
Performance
Perf. 1M
Price performance over the last month.
37.70%
Perf. 3M
Price performance over the last 3 months.
123.40%
Perf. 6M
Price performance over the last 6 months.
93.60%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
65.20%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-1.6%
Perf. 1Y
Price performance over the last 12 months.
172.99%
Perf. 3Y
Price performance over the last 3 years.
-58.90%
Perf. 5Y
Price performance over the last 5 years.
-86.66%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
370.4
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
–
P/B
Price-to-book ratio: market value relative to book equity.
4.3
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
11.7
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
1.8
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
–
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
30.1%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
–
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
-51.1%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-41.0%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-6.6%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
–
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
1.3
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
4.31
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
5 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
40.50%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
-32.70%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
-28.34%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
7.33%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
19.00%
Dividend
This stock currently pays no dividend.
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
2
Top 10%
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
93
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
19
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
5 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
B (55 out of 100)
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
4.31
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
Current Price
6.60 $
Price Target (average)
5.70 $
The price target sits 13.6% below the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
6. Aug 2026
· after the close
· Q2 2026
- Expected Earnings per Share
- -0.07 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.19 | – | 56 | -23.90 | -46.40 | -15 | -21 |
| 2025: Q1 | -0.21 | – | 47 | -27.00 | -63.90 | -9 | -15 |
| 2025: Q2 | -0.27 | – | 47 | -35.40 | -83.50 | -10 | -13 |
| 2025: Q3 | -0.18 | – | 42 | -36.20 | -61.40 | -15 | -18 |
| 2025: Q4 | -0.25 | – | 50 | -11.60 | -71.60 | -23 | -25 |
| 2026: Q1 | -0.03 | – | 66 | 40.50 | -5.70 | 9 | 4 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Maravai LifeSciences Holdings, Inc., ein Life-Sciences-Unternehmen, bietet Produkte, die die Entwicklung von Arzneimitteltherapien, Impfstoffen, Zell- und Gentherapien sowie Diagnostika in Nordamerika, Europa, im Nahen Osten, in Afrika, im asiatisch-pazifischen Raum sowie in Latein- und Mittelamerika ermöglichen.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 416 |
| Headquarters | San Diego, CA |
| Website | maravai.com |
| IPO Date | 20. Nov 2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert Andrew Eckert M.B.A. | Chairman of the Board | 1962 |
| Bernd Brust | CEO & Director | 1967 |
| Rajesh J. Asorpota | EVP & Chief Financial Officer | 1967 |
| Kurt A. Oreshack J.D. | Executive VP, General Counsel & Secretary | 1981 |
| Christine Dolan | Executive VP & GM of Cygnus Technologies | 1968 |
| Chanfeng Zhao | Senior VP & Chief Scientific Officer | – |
| Debra Hart | Senior Director of Investor Relations | – |
| Judith A. Solecki | Senior VP & Chief Human Resources Officer | – |
| Kate E. Broderick Ph.D. | Executive Vice President | – |
| Christopher C. Benoit | Executive VP & Advisor | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.